Gudrun Russ

422 total citations
14 papers, 283 citations indexed

About

Gudrun Russ is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gudrun Russ has authored 14 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Genetics and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gudrun Russ's work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Gudrun Russ is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Gudrun Russ collaborates with scholars based in Austria, Switzerland and Germany. Gudrun Russ's co-authors include Richard Greil, Cornelia Lass‐Flörl, Michael Girschikofsky, Michael Fridrik, David Nachbaur, Arié Figer, Paul Knöbl, Laurent Mineur, Christian Geltner and Pierre Étienne and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Clinical Microbiology.

In The Last Decade

Gudrun Russ

13 papers receiving 277 citations

Peers

Gudrun Russ

ONCOL

EPIDE

PRM

HEMAT

Jorge Garces United States

Giulia Tolomelli Italy

Benquan Wu China

Liang‐Piu Koh Singapore

Ryuji Ieki Japan

T. Suedhoff Germany

Elisa López‐Fernández Spain

Elise Toussaint France

Alexander Burchardt Germany

A. Escudero Spain

Jorge Garces United States

Gudrun Russ

109 ×0.9

ONCOL

59 ×0.5

128 ×1.1

EPIDE

37 ×0.6

PRM

15 ×0.4

HEMAT

Citations per year, relative to Gudrun Russ Gudrun Russ (= 1×) peers Jorge Garces

Countries citing papers authored by Gudrun Russ

Since Specialization

Citations

This map shows the geographic impact of Gudrun Russ's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gudrun Russ with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gudrun Russ more than expected).

Fields of papers citing papers by Gudrun Russ

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gudrun Russ. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gudrun Russ. The network helps show where Gudrun Russ may publish in the future.

Co-authorship network of co-authors of Gudrun Russ

This figure shows the co-authorship network connecting the top 25 collaborators of Gudrun Russ. A scholar is included among the top collaborators of Gudrun Russ based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gudrun Russ. Gudrun Russ is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Lass‐Flörl, Cornelia, Maria Aigner, Katharina Grif, et al.. (2012). Utility of PCR in Diagnosis of Invasive Fungal Infections: Real-Life Data from a Multicenter Study. Journal of Clinical Microbiology. 51(3). 863–868. 53 indexed citations

Wöll, Ewald, Richard Greil, Wolfgang Eisterer, et al.. (2011). Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).. PubMed. 31(12). 4439–43. 12 indexed citations

Worel, Nina, Peter Neumeister, H. Kasparu, et al.. (2010). Plerixafor and granulocyte–colony‐stimulating factor (G‐CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G‐CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion. 51(5). 968–975. 31 indexed citations

Perkhofer, Susanne, Cornelia Lass‐Flörl, Michaela M. Hell, et al.. (2010). The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. International Journal of Antimicrobial Agents. 36(6). 531–536. 79 indexed citations

Mlineritsch, Brigitte, Johannes Andel, Michael Fridrik, et al.. (2009). Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer. Oncology Research and Treatment. 32(1-2). 18–24. 12 indexed citations

Eisterer, Wolfgang, Michael Fridrik, Birgit Grünberger, et al.. (2009). Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). Journal of Clinical Oncology. 27(15_suppl). 4538–4538. 11 indexed citations

Döhner, Konstanze, Ingo G.H. Schmidt‐Wolf, Francisco del Valle, et al.. (2008). Role of Etoposide in Combination with All-Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation. Blood. 112(11). 559–559. 4 indexed citations

Eisterer, Wolfgang, Michael Fridrik, Birgit Grünberger, et al.. (2008). Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric- 2. Journal of Clinical Oncology. 26(15_suppl). 15587–15587. 10 indexed citations

Egle, Alexander, Lukas Weiß, Franz Josef Gassner, et al.. (2008). Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study. Blood. 112(11). 3175–3175. 3 indexed citations

10.

Pleyer, Lisa, et al.. (2007). Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C. Wiener klinische Wochenschrift. 119(7-8). 254–258. 9 indexed citations

11.

Egle, Alexander, Lukas Weiß, Gudrun Russ, et al.. (2007). Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos Study.. Blood. 110(11). 2045–2045.

12.

Egle, Alexander, et al.. (2006). Planned First Safety and Efficacy Analysis of Oral Fludarabine Combined with Subcutaneous Alemtuzumab in 2nd Line Therapy of B-Chronic Lymphocytic Leukaemia (B-CLL): The FLUSALEM Study.. Blood. 108(11). 4990–4990. 1 indexed citations

13.

Mlineritsch, Brigitte, et al.. (2004). Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure. Oncology Research and Treatment. 27(5). 441–446. 16 indexed citations

14.

Gramont, Armand de, Andrés Cervantes, Thierry André, et al.. (2004). OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Journal of Clinical Oncology. 22(14_suppl). 3525–3525. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact